Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Medtronic
AstraZeneca
Boehringer Ingelheim
Merck

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Litigation Details for Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC (N.D. Ill. 2012)

See Plans and Pricing

« Back to Dashboard

Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC (N.D. Ill. 2012)

Docket   Start Trial Date Filed 2012-05-17
Court District Court, N.D. Illinois Date Terminated
Cause 35:271 Patent Infringement Assigned To Rebecca R. Pallmeyer
Jury Demand None Referred To
Parties CUMBERLAND PHARMACEUTICALS INC.; MYLAN INC.; MYLAN INSTITUTIONAL LLC
Patents 8,148,356; 8,399,445
Attorneys Amy Yongmee Cho; Benjamin Thomas Sirolly; Catherine Leigh Gibbons; Danielle Andrea Duszczyszyn; Elham Firouzi Steiner; Elizabeth A.F. Morris; Laura Pollard Masurovsky; Lynn Hagman Murray; Mark Jeremy Feldstein; Nancy Zhang; Nicole Stafford; Robert A. Delafield , II; Stephen J. Rosenfeld; Steven L Baron; Steven L. Baron; Steven P. Mandell; Stuart Williams; Tung-On Kong; Wendy L Devine
Link to Docket External link to docket
Small Molecule Drugs cited in Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC (N.D. Ill. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-05-17 1 Cumberland is the owner of U.S. Patent No. 8,148,356 (“the ’356 patent”), entitled “Acetylcysteine Composition…-7164586. (Attachments: # 1 Exhibit U.S. Patent No. 8,148,356)(Murray, Lynn) (Entered: 05/17/2012) … (A) A declaration that United States Patent No. 8,148,356 is valid and enforceable; (…This is a complaint for patent infringement and for declaratory judgment of patent infringement. The jurisdiction… Count I - Patent Infringement of the ’356 Patent 13. Cumberland realleges External link to document
2013-05-24 131 Contentions”) with regard to U.S. Patent No. 8,148,356 (“the ‘356 patent”). I. INTRODUCTION …liable for infringement of the ‘356 patent. Despite filing a patent lawsuit in this district, Cumberland… the ‘356 patent and grant Mylan’s pending Motion for Summary Judgment for the ‘356 patent. IV. …Cumberland Pharmaceuticals Inc.’s (“Cumberland”) Local Patent Rule 3.1 Final Infringement Contentions (“Final…injection product (“ANDA product”) infringes the ‘356 patent. Cumberland did so after declining to accept Mylan External link to document
2013-05-29 135 contentions on Cumberland’s United States Patent No. 8,399,445, recently added by consent in this case.…Procedure, this Court’s Scheduling Order, and the Local Patent Rules. Accordingly, the Motion to Strike should…faithfully comply with the requirements of the Local Patent Rules (“Rules”). Mylan’s reliance on the preamble…Notably, the section of the Preamble in the Local Patent Rules Mylan does not cite, states: The…case. It is not unusual for a party in a patent case to learn additional grounds for claims of External link to document
2014-02-26 187 infringement of two patents related to Acetadote: United States Patents No. 8,148,356 and No. 8,399,445.…are two patents Cumberland holds related to Acetadote: No. 8,148,356 ("the '356 patent")…as EDTA 2." U.S. Patent No. 8,148,356, hereinafter "'356 patent," abstract (filed …No. 8,399,445 ("the '445 patent"). The '356 patent, which issued on April 3, 2012, …;445 patent claims the methods of administering the compositions covered by the '356 patent. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Baxter
McKesson
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.